A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy — MAJESTY

Primary Membranous Nephropathy Clinical Trial

Official title:
A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy

Status Active, not recruiting

Clinical Trial Summary

This study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04629248
Study type	Interventional
Source	Hoffmann-La Roche
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	June 25, 2021
Completion date	December 29, 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05800873` - Evaluate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of EVER001	Phase 1
Recruiting	`NCT05514015` - Clinical Study of Rituximab Combined With Corticosteroids or Rituximab Monotherapy in the Treatment of Primary Membranous Nephropathy	Phase 4
Recruiting	`NCT05668403` - A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy	Phase 1
Recruiting	`NCT05696613` - A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy	Phase 3
Recruiting	`NCT05862233` - A Clinical Study of MIL62 in Primary Membranous Nephropathy	Phase 3
Not yet recruiting	`NCT06120673` - REmission in Membranous Nephropathy International Trial (REMIT)	Phase 3
Recruiting	`NCT05398653` - A Clinical Study of MIL62 in Primary Membranous Nephropathy	Phase 1/Phase 2
Active, not recruiting	`NCT05136456` - Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy	Phase 2
Recruiting	`NCT05707377` - A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy	Phase 2/Phase 3